1134327-76-6 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl 4-(2-fluorobenzoyl)piperidine-1-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its specific structure allows it to be a key component in the development of new medications, potentially offering novel therapeutic options for a range of medical conditions.
Used in Material Science:
In the field of material science, tert-butyl 4-(2-fluorobenzoyl)piperidine-1-carboxylate is used as a precursor in the synthesis of advanced materials. Its reactivity and functional groups can contribute to the creation of new materials with unique properties, such as improved stability, enhanced reactivity, or specific interactions with other molecules.
Used in Organic Chemistry Research:
Tert-butyl 4-(2-fluorobenzoyl)piperidine-1-carboxylate is used as a research compound in organic chemistry. Its potential for controlled reactions and the possibility of exploring its interactions with other molecules make it an interesting subject for scientific investigation. This research could lead to a better understanding of the compound's properties and applications, as well as the development of new synthetic methods and techniques.
Check Digit Verification of cas no
The CAS Registry Mumber 1134327-76-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,4,3,2 and 7 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1134327-76:
(9*1)+(8*1)+(7*3)+(6*4)+(5*3)+(4*2)+(3*7)+(2*7)+(1*6)=126
126 % 10 = 6
So 1134327-76-6 is a valid CAS Registry Number.
1134327-76-6Relevant articles and documents
QUINOXALINE DERIVATIVES AS GPR6 MODULATORS
-
Paragraph 0229-0232, (2014/03/22)
The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.